



Micheline Gravelle and Iris Cheung coauthored an article "Pricing, patents and the PMPRB in Canada" by LSIPR

December 22, 2020

Micheline Gravelle and Iris Cheung coauthored an article "Pricing, patents and the PMPRB in Canada", published by the Life Sciences Intellectual Property Review.

Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada's federal drug price regulator—and its likely implications.

The price of patented medicines in Canada is regulated by the Patented Medicine Prices Review Board (PMPRB), an independent, quasi-judicial body established under the Patent Act to ensure the prices of patented medicines are not excessive.

The PMPRB exercises its regulatory mandate by monitoring the factory gate price of patented medicines and ordering remedies when the price is determined to be excessive. It has jurisdiction only on patentees and has no regulatory power over distributors of patented medicines.

[Click here to read full article.](#)

This article was first published by the [Life Sciences Intellectual Property Review](#) on December 14, 2020.

Update after publication: Health Canada has announced that the implementation of the Patented Medicines Regulations and Final PMPRB Guidelines has been delayed for 6 months to July 1, 2021.